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CASE PRESENTATION
A 76-year-old woman, who sustained an accidental fracture
of the femoral neck, developed hyponatremia after
admission. The diagnosis of the syndrome of inappropriate
secretion of antidiuretic hormone (SIADH) was made by the
consulting internist and fluid restriction of 700 cc/day was
instituted. Her serum sodium (Na) fluctuated between 122
and 129 mmol/l and a renal consultation was requested on
the eighth day after undergoing a hemiarthroplasty of the
hip when she was ambulating and on no pain medication.
Her blood pressure was 100/60 mm Hg, pulse 92 beats/min
and there was poor tissue turgor, flat jugular veins, and dry
mucous membranes. There was no edema, third spacing,
postural hypotension or neurological abnormalities. Her
medications included docusate sodium, milk of magnesia,
simvastatin, and warfarin. She was not on drugs such as
atorvastatin, fenofibrate, or losartan which reduce serum
urate by increasing renal urate excretion.1–3 A low baseline
urine Na (UNa) concentration of 6 mmol/l suggested a
hypovolemic condition with normal renal function4 that
should result in a prerenal state characterized by low UNa,
azotemia, and hyperuricemia. The baseline serum urate of
3.4 mg/dl, however, was inconsistent with prerenal
azotemia and its coexistence with hyponatremia was
suggestive of SIADH or renal salt wasting.4–6 The patient
was, therefore, included in an IRB-approved protocol to
differentiate SIADH from renal salt wasting.
After obtaining an informed consent, a blood volume
study was performed, using a radioisotope dilution
technique.7 With a hematocrit of 31%, the red cell volume
was decreased by 28% and the plasma volume increased
by 4.7%, resulting in a net blood volume reduction of
7.1%. The pertinent baseline laboratory data are
summarized in Table 1. The baseline plasma renin,
aldosterone, antidiuretic hormone (ADH), and fractional
urate excretion were elevated at 8.63 ng/ml/h, 16.5 ng/dl,
2.5 pg/ml, and 29.6% (normal 5–10%), respectively. Plasma
osmolality was decreased at 260 mosM/kgH2O, atrial
natriuretic peptide was in the low normal range at
35 pg/ml, serum phosphorus and urate were decreased
at 2.4 and 3.4 mg/dl, respectively. Renal, adrenal, and
thyroid functions were normal. The chest X-ray and
urinalysis were normal.
Saline was then infused at 125 ml/h for 48 h. Urine
osmolality of all spontaneously voided urine was
immediately determined and when her urine osmolality
decreased to 152 mosM/kgH2O at 13.3 h, a repeat plasma
ADH was undetectable when the serum osmolality was
268 mosM/kgH2O. At this time, she had received 1660 ml of
saline overnight and excreted 955 ml of urine. The plasma
renin and aldosterone decreased to 2.95 ng/ml/h and
7.6 ng/dl, respectively, and plasma atrial natriuretic peptide
increased to a high normal 65 pg/ml. The serum Na
remained unchanged at 129 mmol/l but the serum urate
decreased from 3.4 to 1.7 mg/dl. It should be noted that
the baseline urine osmolality of 321 mosM/kgH2O increased
to 587 mosM/kgH2O and the UNa only increased from a
baseline of 6 to 18 mmol/l in the first urine passed 4 h after
initiation of saline infusion (Figure 1, Table 2). The serum
Na gradually increased from 129 to 138 mmol/l at 45.8 h
(Figure 2), as serum urate decreased to 1.0 mg/dl and
fractional urate excretion remained elevated (Figure 2). Her
UNa increased to a peak of 82 mmol/l at 8.1 h (Table 2). At
16 h, she awoke refreshed and hungry, suggesting that the
fluid restriction for treatment of SIADH exacerbated her
volume depletion, induced weakness, lethargy, and
anorexia, which accounted for the low baseline UNa of
6 mmol/l. Fractional Na excretion gradually increased from
0.11 to 2.86% (Table 2), serum creatinine decreased from a
baseline of 0.8 to 0.5 mg/dl at 13.3 h and creatinine
clearance increased from 38.2 to 74.6 ml/min over the
same period. Fractional potassium (K) excretion was 13.2%
at baseline, decreased to 7.9% at 4 h and fluctuated
between 2.7 and 4.5% as did serum K between 4.5 and
4.7 mmol/l (Table 2). The baseline fractional phosphate
excretion of 12.7% increased to 72.9% at 6.1 h
(Table 2).
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CLINICAL FOLLOW-UP
The patient was discharged 2 days after completion of the
renal studies and was lost to follow-up.
DISCUSSION
We present compelling evidence of renal salt wasting in a
hyponatremic patient with a hip fracture, persistent hypo-
uricemia, and elevated fractional urate excretion after
correction of hyponatremia, and no clinical evidence of
cerebral disease, where a serum urate determination was
pivotal in the clinical assessment of the patient. Without the
7.1% reduction in blood volume determination, a test not
routinely used in this clinical setting, the initial UNa of
6 mmol/l was more consistent with a hypovolemic prerenal
state that is characterized by avid renal conservation of Na,
urea, urate, and other solutes, leading to hyperuricemia and
azotemia.4 The hypouricemia and elevated fractional urate
excretion indicated a reduction in tubular urate transport
that was not consistent with prerenal azotemia and their
coexistence with hyponatremia was more consistent with
SIADH and renal salt wasting.4–6,8 Without an appreciation
of this coexistence of hyponatremia and hypouricemia, the
low UNa of 6 mmol/l could have led to a diagnosis of
prerenal azotemia.4 The elevated plasma renin, aldosterone
and ADH and low normal atrial natriuretic peptide levels are
all physiologic consequences of the decrease in blood volume
resulting from renal salt wasting, but these determinations
were not available on first encounter to be of diagnostic value
(Figure 3). Finally, to add to the dilemma and instructive
value of this case, the clinical absence of cerebral disease
probably eliminated renal salt wasting from the differential by
the consulting internist, who erroneously diagnosed SIADH,
instituted fluid restriction, exacerbated the volume depletion
and induced lethargy, anorexia, low sodium intake, and
low UNa. It should be noted that UNa in SIADH and renal
salt wasting reflects Na intake and can be low if Na intake
is low.
The initiation of saline infusion supports the diagnosis of
renal salt wasting and provides insights into the handling of
Na, urate, K, and phosphate in renal salt wasting. The most
compelling consequence of the saline infusion other than the
dramatic clinical improvement was the illustration of the
physiologic consequences of renal salt wasting. Because the
hypovolemic stimulus for ADH secretion over rides the
inhibition by the coexistent hypoosmolality of plasma, the
increased ADH levels produced a defect in free water
excretion or inability to extract pure water from the blood
and tendency to develop hyponatremia. The saline infusion
eliminated the volume stimulus for ADH secretion and
permitted the coexistent hypoosmolality to inhibit ADH
secretion, leading to undetectable plasma ADH levels,
generation of dilute urines, and prompt correction of the
hyponatremia (Figure 1). Additionally, the persistence of
hypouricemia and increased fractional urate excretion after
correction of the hyponatremia provided additional evidence
for renal salt wasting and not SIADH (Figure 2), vide infra.4–6
It might be argued that saline increased fractional urate
excretion. The fractional urate excretion of 29.6% at baseline
is significantly higher than the 4% that is observed in volume
depleted subjects with normal renal function.8 As noted in
our review of urate transport, normal, hypotonic, and
hypertonic saline increased fractional Na excretion to as
high as 18.5% but fractional urate excretion only increased to
12.1%.6 The fractional urate excretion of 63.1% at 19.6 h
when fractional Na excretion was only 1.35% suggests that
Table 1 | Summary of pertinent baseline data
Serum/blood
Na K Cl CO2 BUN Cr Uric acid PO4 Ca Osm Hg Hct
(mmol/l) (mmol/l) (mmol/l) (mmol/l) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mosm/kg) (g/dl) (%)
129 3.8 106 23 16 0.8 3.4 2.4 8.5 260 10.6 31
Hormones
ADH Renin Aldo ANP Cortisol TSH T4
(pg/ml) (ng/ml/h) (ng/dl) (pg/ml) (mg/dl) mIU/l (mg/dl)
2.5 8.63 16.5 35 26.9 5.04 7.31
Urine
Uosm UNa FEUA FENa FEK FEPO4
(mos m/kg) (mmol/l) (%) (%) (%) (%)
321 6 29.6 0.11 13.2 12.7
ADH, antidiuretic hormone; ANP, atrial natriuretic peptide; BUN, blood urea nitrogen; FEK, fractional K excretion; FENa, fractional Na excretion; FEPO4, fractional phosphate
excretion; FEUA, fractional excretion of uric acid; Osm, osmolality; TSH, thyroid stimulating hormone; UNa, urine Na; Uosm, Urine osmolality.
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Figure 1 | Urine osmolality and serum sodium concentration
during saline infusion at 125 ml/h. Serum osmolality ranged
between 260 and 268 mosM/kgH2O in the first 15 h of the study.
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saline had a minor effect on fractional urate excretion and
negate the notion that volume expansion induces the increase
in fractional urate excretion in SIADH.9 Finally, this case
supports our previous recommendation to eliminate ‘cere-
bral’ in favor of ‘renal’ in salt wasting syndromes, as the
absence of clinical cerebral disease would eliminate renal salt
wasting from the differential when evaluating hyponatremic
patients.5,6
Cerebral salt wasting has been considered a rare clinical
entity and even a misnomer of SIADH,2,8,10 especially among
internists and nephrologists. Neurosurgeons, however, con-
sider cerebral salt wasting to be common.11–13 The major
reason for this discrepancy lies in our inability to assess
accurately the volume status of a patient on the basis of
clinical criteria and many overlapping clinical and laboratory
findings in both diseases.4,5,14 Both are characterized by
hyponatremia, hypouricemia, concentrated urine, UNa
usually exceeding 20 mmol/l, and clinical associations that
include intrathoracic disease, intracranial disease, and
malignancies.4–6,15,16 As noted in Figure 3, extracellular
volume is high normal or increased in SIADH and decreased
in renal salt wasting. ADH levels are elevated in both
conditions but are inappropriate in SIADH and appropriate
in renal salt wasting. As noted in Figure 3, hormonal
adjustments such as renin, aldosterone, and atrial or brain
Table 2 | Summary of time (h), UNa (mmol/l), FENa (%), FEK (%), serum K (mmol/l), FEPO4 (%), and serum phosphorus (mg/dl) at
baseline and during 125 ml/h saline infusion
Hours UNa FENa FEK Serum K FEPO4 Serum PO4
(mmol/l) (%) (%) (mmol/l) (%) (mg/dl)
0 6 0.11 13.2 3.8 12.7 2.4
4 18 0.68 7.9 4.7 — —
6.1 55 0.65 4.5 — 62.9 —
8.1 82 0.78 3.2 — 59.1 2.3
10.8 63 0.79 2.7 — 50.9 —
12.3 42 0.82 4.0 — 58.5 —
13.1 27 0.69 3.5 4.6 69.6 2.2
13.3 — 1.11 — — — —
14.3 46 1.59 3.5 — 76.0 —
15.6 72 1.5 3.5 — — 2.1
17.6 62 — — — — —
19.6 90 1.35 3.1 — — —
27.8 — 1.80 5.3 — — —
40.8 87 2.86 4.4 4.5 — —
45.8 71 — — — — —
FEK, fractional K excretion; FENa, fractional Na excretion; FEPO4, fractional phosphate excretion; UNa, urine Na.
Serum Na, serum urate, and FE urate
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Figure 2 | Persistence of hypouricemia and increased fractional
urate excretion after correction of hyponatremia during saline
infusion at 125 ml/h.
Work Up of non-edematous hyponatremia
Check UNa
<20 mmol/l >20 mmol/l
Volume depletion
with normal kidney
function 
SIADH or 
RSW
Check serum and FE urate
Hyperuricemia 
FE urate <10%
Serum urate <4 mg/dl 
FE urate >10%
Azotemia
Volume depletion
with normal kidney function
SIADH or RSW
(see below)
ECV Renin Aldosterone ADH ANP/BNP SUA no. FEUA no.
Differentiation of SIADH from RSW
RSW  ±↑* ↑ ↑  ±↓   
SIADH high N to↑ N to ↓ N to ↓ ±↑  
↓
↑ ↓→N ↑→N
↓→↓ ↑→↑
Figure 3 | Algorithm for work-up of non-edematous
hyponatremia. (a) Work-up of non-esematous hyponatremia.
Suggested step-wise evaluation of a patient with non-edematous
hyponatremia. Interpretation of UNa is not valid in patients taking
diuretics, has chronic renal disease, or is acutely vomiting. UNa in
SIADH and renal salt wasting (RSW) can be low if the patient is on a
low sodium diet as in the present case report. Coexistence of
hypouricemia and hyponatremia will favor the diagnosis of SIADH
and renal salt wasting. (b) Differentiation of SIADH from renal salt
wasting. Major difference is the state of ECV. *Renin levels can be
normal in renal salt wasting if the patient is on a normal to high salt
diet. Renin and aldosterone in SIADH may be low normal to low.
Other than assessment of ECV, the other parameters are not available
on first encounter. ECV¼ extracellular volume, ANPBNP¼ atrial/brain
natriuretic peptide.
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natriuretic peptides can collectively differentiate SIADH from
renal salt wasting, but the only difference on first encounter is
the status of their extracellular volume, which is fraught with
errors without edema, third spacing, or invasive pro-
cedures.5,14 The differentiation of one group from the other is
important because patients with SIADH are water-restricted
as compared to salt and water supplementation in renal salt
wasting. Selecting the wrong mode of therapy can lead to
significant clinical consequences.17,18 The clinical improve-
ment noted after initiation of saline infusion illustrates the
deleterious effects of fluid restriction in our patient.17,18 To
illustrate the clinical consequences of fluid restriction in salt
wasting patients, Wijdick et al.12 noted increased morbidity
and mortality when hyponatremic patients with subarach-
noid hemorrhage were fluid restricted for what was assumed
to be SIADH. Reduced blood volume determinations
consistent with renal salt wasting were noted in eight of
nine hyponatremic patients with subarachnoid hemor-
rhage.12 The frequency of salt wasting noted by Wijdick
et al.12 supported the earlier work by Nelson et al.,11 who
demonstrated a reduction in blood volume in eight of nine
hyponatremic neurosurgical patients with UNa ranging
between 41 and 203 mmol/l11 and later by Sivakumar
et al.13 who reported decreased blood volumes in 17 of 18
patients and central venous pressures to be reduced in all 18
hyponatremic neurosurgical patients with UNa of
24–203 mmol/l. These neurosurgical studies provide the
essential data to support the diagnosis of renal salt
wasting.11–13 It is understandable why the first report of
cerebral salt wasting by Peters et al.16 could be considered a
misnomer of SIADH because the diagnosis of dehydration
with high UNa was based on weak clinical criteria. The first
blood volume determination by Cort19 proved the existence
of renal salt wasting but blood volume determinations in
subsequent reports other than measurements of central
venous pressures or postural hypotension4,6,13,18–20 have been
lacking, thus perpetuating the skepticism of the existence of
salt wasting.14,21
Hypouricemia and increased fractional urate excretion
have been associated with hyponatremia in SIADH and
normalize after correction of the hyponatremia.9,10 This
relationship between serum Na, serum urate and fractional
urate excretion has been reported both clinically and
experimentally.9,10,22 We dissociated serum Na from serum
urate and fractional urate excretion by demonstrating
persistence of hypouricemia and elevated fractional urate
excretion after correction of hyponatremia in patients with
concentrated urine and UNa 420 mmol/l.13 One patient
with postural hypotension responded to volume repletion by
inhibiting ADH secretion and eight hyponatremic patients
with AIDS had central venous pressures of 0 cm H2O, UNa
420 mmol/l, hypouricemia, increased fractional urate excre-
tion and elevated plasma rennin, and aldosterone that
responded to saline infusions.6,13,23 The high UNa and
volume depletion were consistent with renal salt wasting. We
proposed that the persistent hypouricemia and elevated
fractional urate excretion after correction of hyponatremia
identified a group of patients that was clearly different from
SIADH and was most consistent with renal salt wasting.5,6,13
The present case report provides indisputable evidence that
hypouricemia and increased fractional urate excretion persist
after correction of the hyponatremia in renal salt wasting
(Figure 2).
The relationship between serum urate, fractional urate
excretion, and hyponatremia has yet to be clarified.
Hypouricemia has been arbitrarily defined as 1–4 mg/dl as
compared to the more physiologically derived fractional urate
excretion.6 We reported elevations in fractional urate
excretion with serum urate 44 mg/dl in AIDS, and patients
with neurosurgical and Alzheimer diseases.23–25 The increased
fractional urate excretion with or without hypouricemia in
the absence of hyponatremia in the neurosurgical and
Alzheimer patients would be consistent with our proposal
that fractional urate excretion remains elevated without
hyponatremia in renal salt wasting.5,6,13 Alzheimer patients
are not typically hyponatremic, possibly because of reduced
water intake resulting from a defective thirst mechanism of
aging and dementia. We are in agreement with Singh et al.21
that hyponatremia is not a prerequisite for making the
diagnosis of renal salt wasting. Demonstration of natriuretic
activity in the plasma of our neurosurgical and Alzheimer
patients further suggests that increased fractional urate
excretion without hyponatremia might be a feature of renal
salt wasting.25,26 The increase in fractional Na and lithium
excretion rates noted in rats infused with plasma of our
neurosurgical and Alzheimer patients raises an interesting
speculation that a circulating plasma protein might affect Na,
urate, phosphorus, and even urea transport in renal salt
wasting25,26
Previous studies in renal salt wasting have not addressed
the renal handling of Na, K, phosphorus, and urate at
baseline and during volume repletion. It is interesting to note
that fractional potassium excretion decreased during saline
infusion, possibly reflecting the decrease in plasma aldoster-
one levels despite providing a favorable environment for
potassium secretion by increasing Na and flow to the distal
nephron. The increase in fractional phosphate excretion is
not a feature of SIADH and its coexistence with increased
fractional Na and urate excretions is suggestive of a partial
Fanconi syndrome with absence of glucosuria and acidosis.
Fractional phosphate excretion has not been systematically
studied in patients with renal salt wasting for it to be
regarded as a consistent abnormality, but its presence would
be more suggestive of renal salt wasting than SIADH.
Fractional phosphate excretion should, therefore, be deter-
mined when evaluating patients with hyponatremia and
hypouricemia.
In summary, the present case probably represents the tip
of the iceberg in estimating the prevalence of renal salt
wasting and illustrates the need to eliminate the restrictive
and inappropriate term, ‘cerebral’ from salt wasting to
expand our consideration of renal salt wasting beyond the
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cerebrum. The coexistent hypouricemia was consistent with
renal salt wasting or SIADH but the decreased blood volume,
generation of a dilute urine after appropriate inhibition of
ADH secretion with saline, and persistent hypouricemia and
increased fractional urate excretion after correction of the
hyponatremia are consistent with renal salt wasting.5,6,9 This
case, however, does not solve the conundrum of differentiat-
ing SIADH from renal salt wasting on first encounter,
because difference in volume status is the only variable that
differentiates SIADH from renal salt wasting.5,14 Clinical
assessment of extracellular volume is, however, inaccurate.
While renal salt wasting is a definite clinical entity that
deserves serious consideration in any non-edematous hypo-
natremic patient with or without cerebral disease, the
contrasting therapeutic goals make it imperative to develop
more effective guidelines to differentiate renal salt wasting
from SIADH on first encounter (Figure 3).
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